<DOC>
	<DOCNO>NCT02608268</DOCNO>
	<brief_summary>The purpose first-in-human study MBG453 characterize safety , tolerability , pharmacokinetics , pharmacodynamics anti-tumor activity MBG453 administer i.v . single agent combination PDR001 adult patient advance solid tumor</brief_summary>
	<brief_title>Safety Efficacy MBG453 Single Agent Combination With PDR001 Patients With Advanced Malignancies .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically document advanced metastatic solid tumor . Phase IIb part ( include dose range part ) : Patients advanced/metastatic solid tumor , measurable nonmeasurable disease determine RECIST v1.1 , progress despite standard therapy intolerant standard therapy , standard therapy exist receive prior antiPD1/PDL1 treatment . Phase II part ( MBG453 single agent ) : Patients advanced/metastatic solid tumor indication least one confirm PR CR see dose escalation phase I part . Patients must measurable disease determine RECIST v1.1 , progress despite standard therapy intolerant standard therapy . Phase II part ( MBG453 combination PDR001 ) : Patients advanced/metastatic tumor select indication , least one measurable lesion determine RECIST v1.1 , receive standard therapy intolerant standard therapy progress follow last prior therapy . : Melanoma ( antiPD1/PDL1 therapy naïve pretreated ) Non small cell lung cancer ( antiPD1/PDL1 therapy naïve pretreated ) Renal Cell Carcinoma ( antiPD1/PDL1 therapy naïve pretreated ) Must site disease amenable biopsy , candidate tumor biopsy accord treat institution 's guideline . Patient must willing undergo new tumor biopsy screening/baseline , therapy study . Presence symptomatic central nervous system metastasis . History severe hypersensitivity reaction monoclonal antibody . Human Immunodeficiency Virus , Hepatitis B Virus Hepatitis C Virus infection . Active autoimmune disease document history autoimmune disease , include ulcerative colitis Crohn 's disease condition require systemic steroid . Systemic steroid therapy immunosuppressive therapy ( ≥10mg/day prednisone equivalent ) . Use vaccines infectious disease ( e.g . varicella , pneumococcus ) within 4 week initiation study treatment . Pretreatment antiCTLA4 antibody combination antibody drug specifically target Tcell costimulation checkpoint pathway . Participation interventional , investigational nonimmunotherapy study within 2 week first dose study treatment . Prior participation interventional , investigational cancer vaccine immunotherapy study except antiPD1/PDL1 study . Other inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Phase I-Ib/II</keyword>
	<keyword>MBG453</keyword>
	<keyword>PDR001</keyword>
	<keyword>Checkpoint inhibitor</keyword>
	<keyword>PD-1</keyword>
	<keyword>TIM-3</keyword>
</DOC>